Please assess the completion status of the following clinical trial:

Trial Title: SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients at least 20 years of age~* Patients with diagnosed primary cancer~* Patients with metastatic lesions by CT/MRI~Exclusion Criteria:~* Patients who have contraindication to the MRI examinations~* Patients who have severe renal disorder~* Patients in extremely serious general condition

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol 0.1 mmol/kg bw (Type: EXPERIMENTAL): Participants received first injection (intravenous \[i.v.\]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
- Gadobutrol 0.2 mmol/kg bw (Type: EXPERIMENTAL): Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
- Gadoteridol (ProHance) (Type: EXPERIMENTAL): Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min

Based on this trial design, predict the completion outcome and termination type (if applicable).